跳至主要内容
临床试验/NCT01072838
NCT01072838终止2 期

Safety and Feasibility of Short-Course, Accelerated, Hypofractionated Partial Breast Radiotherapy in Women With Early Stage Breast Cancer Using the Contura MLB Breast Brachytherapy Catheter: A Phase II Trial

SenoRx, Inc.6 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2009年12月最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
终止
发起方
SenoRx, Inc.
入组人数
60
试验地点
6
主要终点
Delivery of short-course APBI will result in locoregional disease control that is equal to that reported for conventional fractionation schemes for APBI.

研究概览

简要总结

To determine local disease control (recurrence) with shorter course of APBI delivered with a breast brachytherapy applicator.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Life expectancy > 10 years
  • Lumpectomy with clear margins (negative per NSABP criteria)
  • DCIS and/or invasive carcinoma
  • If invasive, nodes must be negative
  • T stage is Tis, T1 or T2<=3 cm max diameter
  • ER(+) or ER(-)/PR(+)

排除标准

  • Pregnant or breast feeding
  • Active collagen-vascular disease
  • Paget's disease of the breast
  • Prior history of breast cancer
  • Prior breast or thoracic radiotherapy
  • Multicentric carcinoma
  • Synchronous bilateral breast cancer
  • Surgical margins that cannot be assessed or that are positive
  • T Stage is T2>3 cm or greater
  • ER(-)/PR(-)

研究组 & 干预措施

Dose Escalation

Other

干预措施: APBI (Dose Escalation) (Radiation)

Dose Escalation

Other

干预措施: Contura MLB Breast Brachytherapy Catheter (Device)

结局指标

主要结局

Delivery of short-course APBI will result in locoregional disease control that is equal to that reported for conventional fractionation schemes for APBI.

时间窗: 5 years

次要结局

未报告次要终点

研究者

发起方
SenoRx, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验